The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis in one or more cell lines, leading to peripheral cytopenias with a tendency to develop into acute leukemia. Supportive care with red blood cell (RBC) transfusions is the mainstay of treatment, although newer 'low-intensity strategies' such as hypomethylating and immunomodulatory agents are changing treatment patterns. With repeated transfusions comes the risk of transfusional iron overload.
Should Patients with Myelodysplastic Syndromes Undergo Iron Chelation Therapy? New Data Answering the Question
The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis in one or more cell lines, leading to peripheral cytopenias with a tendency to develop into acute leukemia. Supportive care with red blood cell (RBC) transfusions is the mainstay of treatment, although newer 'low-intensity strategies' such as hypomethylating and immunomodulatory agents are changing treatment patterns. With repeated transfusions comes the risk of transfusional iron overload.
However, should patients with MDS undergo iron chelation therapy (ICT)? New data are available that can help to answer this question.
Do Patients with Myelodysplastic Syndromes Suffer Organ Impairment from Iron Overload or Is this Identified Only in Children with Thalassemia or Sickle Cell Anemia?
million individuals in the Medicare database, 726,936 (42%) suffered cardiac disease during the three-year study, significantly fewer than in the MDS cohort (p<0.001). MDS patients who received blood transfusions experienced a higher rate of cardiac events: 260 transfused MDS patients (80%) experienced a cardiac event compared with 262 MDS patients (69%) who did not receive transfusions (p=0.002). 4 Additional analysis from this cohort has noted that transfused MDS patients were more likely to develop other comorbidities: diabetes 45 versus 38% (p=0.09), dyspnea 64 versus 39% (p<0.01), hepatic events 2.2 versus 1.7% (p=0.68), and infectious complications 81 versus 57% (p<0.01). Transfused MDS patients were also more likely to transform to acute myeloid leukemia (AML) (19 versus 5%; p<0.01) and had a significantly higher mortality rate at three years (63 versus 33%; p<0.01).
After adjusting for age, transfusion MDS patients were associated with an increased risk for death compared with their non-transfused MDS counterparts (hazard ratio [HR] 2.14; p<0.01). 5 [15] [16] [17] Thus, it appears that we are able to identify lower-risk MDS patients who may survive long enough to suffer the consequences of iron overload and also to identify a level of iron in which toxicity begins.
Will Iron Chelation Therapy Reduce the Iron Burden Among Patients with Myelodysplastic Syndromes?
The use of prolonged subcutaneous deferoxamine was not widespread among patients with MDS. 18 However, the development of a convenient once-daily oral iron chelator, deferasirox (Exjade ® , Novartis Oncology), which has been better accepted by patients, has resulted in a re-evaluation of the role of ICT in this patient population. [19] [20] [21] In the deferasirox licensing trial (Study 108), 47 patients with transfusion-dependent myelodysplasia (median age 66 years) were enrolled. Net iron balance was achieved with 10mg/kg/day and negative iron balance was reached with 20-30mg/kg/day, despite ongoing transfusion requirements. Overall, liver iron content (LIC) changes were dependent on the deferasirox dose (p<0.001) and transfusional iron intake (p<0.01). Changes in serum ferritin and LIC were correlated, thus supporting the potential use of serum ferritin for monitoring deferasirox therapy. Deferasirox had a safety profile compatible with long-term use; the most common adverse events were gastrointestinal disturbances, skin rash, and non-progressive serum creatinine increases. In the multivariate analysis, the use of appropriate good chelation strategies was found to be a favorable prognostic factor for overall survival.
Similarly, patients with lower IPSS, patients who were receiving fewer than three units of blood per month, and patients <77 years of age all fared better. 31 These retrospective studies, with appropriate caution for selection bias, suggest that ICT may favorably influence survival in MDS, similar to the well-known beneficial survival effects of ICT among children with thalassemias.
Is Deferasirox Chelation Therapy Safe for an Elderly Patient with Myelodysplasia?
In the US 03 trial of deferasirox chelation therapy in 173 patients with low-or intermediate-risk MDS, 3% discontinued because of serious adverse events and 10% discontinued because of suspected adverse events. Of 147 patients with normal baseline serum creatinine, 26
(18%) increased the upper limit of normal (ULN) (maximum 3mg/dl).
New onset of thrombocytopenia and neutropenia was reported in nine of 172 (5%) and 22 of 168 (13%), respectively; none were suspected to be related to ICT. 23 In the EPIC trial, of the 341 MDS patients, 166 (49%) discontinued therapy. Reasons for withdrawal included 13% for drug-related adverse events and 2% for unsatisfactory therapeutic effect. Gastrointestinal complaints may be more frequent in this elderly MDS population compared with children, with diarrhea and nausea being the most common adverse events responsible for treatment discontinuation. 21 Ongoing food interaction trials with deferasirox are evaluating safety and tolerability questions to increase medication compliance and retention.
Conclusions
In the last decade, the management of patients with MDS has advanced dramatically, with the development of prognostic scoring systems and low-intensity therapies that are improving outcomes. However, as transfusional support remains the mainstay of treatment, an awareness of the potential toxicities and concerns surrounding transfusion-related iron overload is needed. As discussed in this article, recent data suggest that oral ICT with deferasirox can be effective and well-tolerated in this group of elderly individuals. Therefore, it is now imperative for the hematologist caring for patients with MDS to re-examine the role of iron chelation in this population. n 
